The approach will address “bottlenecks” that slow the traditional antibody discovery process, and it aims to make it possible to generate monoclonal antibody therapies against any target of interest.

By 2017, on the back of the opioid crisis, the rate of neonatal opioid withdrawal syndrome in the U.S. was estimated to have reached 7.3 per 1000 deliveries. Meanwhile, many newborns exposed to opioids in utero never develop the syndrome and must undergo needless monitoring in the hospital after birth.

The milestone surgery resulted from collaboration and exemplifies a generational shift taking place in pediatric surgery.

The pilot project, which is expected to digitize 500,000 slides over three years, aims to open avenues for research, assist with access to whole-slide images for education and clinical meetings (of tumor boards, for example), and facilitate planning for the implementation of digital pathology for diagnostic purposes. 

The leader of the new initiative, Tae Hyun Hwang, PhD, will work to apply AI and other revolutionary technologies, including advanced molecular imaging techniques, to clinical practice.

At neurology clinics the system was used to flag 8% of arriving patients as having relatively high risk for suicide attempt in the next 30 days.

Using AI, a team identified a gap in post-market drug safety: not all published reports of dangerous drug interactions are taken up by recognized purveyors of drug safety information.